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MinireviewSensing and Signaling in AntiviralLuke A.J. O’Neill and Andrew G. Bowie
Viruses are detected by the innate immune system, leading
to the initiation of the anti-viral immune response via the
production of type I interferons and inflammatory cyto-
kines such as interleukin-1. Remarkable progress has
been made over the past few years towards understanding
the contribution of Toll-like receptors, RIG-I like receptors,
NOD-like receptors and HIN-200 family members to viral
detection. Furthermore, new complexities in the signaling
pathways activated by these receptors continue to be
revealed. Together, these new insights are leading to ther-
apeutically useful information in the fight against viruses.
Introduction
In the first line of defense against viruses, type I interferons
(IFNa and IFNb) and cytokines such as interleukin-1b
(IL-1b) initiate the host anti-viral response. Much effort has
gone into elucidating the pattern-recognition receptors that
sense viral components and the downstream intracellular
signaling pathways that lead to IFN and IL-1b induction.
The discovery in 2000 that two proteins from the vaccinia
virus interfere with Toll-like receptor (TLR) signaling was
the first indication that TLRs might be important in the
sensing of viruses [1]: at that point the best characterised
TLR was TLR4, which senses lipopolysaccharide, a compo-
nent of the cell wall of Gram-negative bacteria. When either
of the genes encoding these vaccinia proteins was deleted
from the viral genome, the infectivity of the resulting virus
was attenuated in vivo, pointing to the importance of these
proteins in virulence [2,3]. Subsequently, tremendous prog-
ress was made in revealing the role of TLRs and other innate
immune receptors in anti-viral defense [4]. At the cell surface
and at endosomal compartments, TLRs recognise both DNA
and RNA viruses. In later studies, additional sensors of viral
nucleic acids were identified and found to localise to the
cytosol, notably the RIG-I-like receptors (RLRs) RIG-I and
MDA5, which can sense RNA viruses, and DAI, which can
sense DNA viruses [4]. NOD-like receptor (NLR) family
members were also shown to engage with both DNA and
RNA viruses, in particular the NLR NALP3, which activates
caspase-1 in the inflammasome, leading to the production
of the cytokines IL-1b and IL-18 [4]. More recently, the HIN-
200 family protein AIM2, which also activates caspase-1,
has been shown to sense DNA viruses such as vaccinia [5].
We therefore now have a greatly improved understanding
of the innate sensing of viruses. Here, we review recent find-
ings in this area that reveal additional complexity in terms of
sensing and signaling of viruses by these receptor systems.Growing Role for TLRs in Anti-Viral Signaling
Work on TLR signaling pathways in viral sensing continues to
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ated regulation of the activation of IFN regulatory factor 3
(IRF3), one of the critical transcription factors for IFNb induc-
tion. Both of these TLRs promote activation of IRF3 via
the adapter protein TRIF, which leads to the activation of
the kinase TBK1 and subsequent phosphorylation of IRF3.
Palsson-McDermott et al. [6] have reported insights into
a specific negative regulator of TRAM, the TRIF-related
adapter molecule used exclusively by TLR4 to recruit TRIF:
this protein is termed TRAM adapter with GOLD domain
(TAG) and is a splice variant of TRAM that acts at the late
endosome to displace TRIF from the TLR4–TRAM complex
and limit activation of IRF3. Knockdown of TAG with small
interfering RNA (siRNA) boosts the IRF3 pathway and this
approach could be useful as a vaccine adjuvant to promote
type I IFN production, given that the TRAM–TRIF pathway
has been shown to be especially important for adjuvancy.
Insertion of the gene encoding TRAM into a vaccine DNA
vector with a sequence encoding an HIV peptide led to a
threefold stimulation of the in vivo CD8+ T-cell response to
this peptide [7]. These kinds of approach might lead to better
vaccine adjuvants.
In another study, the basis for how TLR4 can signal to NFkB
(which is required for both IFNb and IL-1b induction) on the
one hand, and IRF3 on the other has been determined [8]
(Figure 1). Tumor necrosis factor (TNF) receptor associated
factor 3 (TRAF3) is a key regulator of both pathways but
it acts in different ways. In the case of NFkB activation,
TRAF3 undergoes ubiquitin-mediated degradation during
signaling mediated by the MyD88 adaptor protein, and this
degradation of TRAF3 allows the MyD88 signaling complex
to translocate to the cytosol to engage with the kinase TAK-1.
The degradation-associated K48-linked ubiquitination of
TRAF3 is performed by cIAP2, itself a ubiquitin E3 ligase
that is activated via non-proteolytic, regulatory K63-linked
ubiquitination by TRAF6 after TLR4 stimulation. In the case
of IRF3 activation, a separate pool of activated TLR4
complexes comprising TLR4 and TRAM translocates to the
endosome, where TRAF3 is recruited and undergoes K63-
linked ubiquitination. This modification of TRAF3 appears
to be required for IRF3 activation by TLR4 and probably
also by TLR3 [8]. These events are therefore likely to be
important for the induction of anti-viral cytokines by these
TLRs.
A further role for ubiquitination in TLR3 and TLR4 signalling
has been uncovered by the finding that the E3 ubiquitin
ligase Nrdp1 can preferentially promote the induction of
type I IFNs by these TLRs, at the expense of pro-inflamma-
tory gene expression [9]. Nrdp1 mediates K48-linked ubiqui-
tination of MyD88 leading to MyD88 degradation, while also
stimulating K63-linked ubiquitination of TBK1, leading to its
activation and IFN induction. Nrdp1 was shown to protect
mice from vesicular stomatitis virus infection because of its
ability to promote IFN production. The TRAF3 and Nrdp1
studies reveal an increasingly complex picture of ubiquitin
E3 ligases in TLR signaling, which would seem to have
a role at least as important as that of kinases.
As well as TLR3 and TLR4, TLR2 has recently been a
surprising addition to the list of TLRs capable of mediating
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Figure 1. Recent developments in TLR-mediated sensing of viruses.
New insights have emerged regarding the regulation of TLR4 and TLR3 signaling, as well as new roles for TLR2 and TLR7 in the response to certain
viruses. (A) TRAF3 is an important inhibitor of plasma membrane signaling by TLR4, a TLR implicated in the response to herpes simplex virus
(HSV), vaccinia, Rous sarcoma virus (RSV) and hepatitis C virus (HCV). TRAF3 is degraded following cIAP2-mediated, K48-linked ubiquitination
(K48 Ub), which requires TRAF6-mediated K63-linked ubiquitination (K63 Ub) of cIAP2. This releases the MyD88 signaling complex, which
engages via TRAF6 with TAK1 leading to NF-kB activation. The TLR4–TRAM complex translocates to the early endosome, where, via TRIF, it acti-
vates TBK1 leading to IRF3 activation. This also requires TRAF3, but in this case, TRAF3 is modified by K63-linked (not K48-linked) ubiquitination.
The TRAM splice variant TAG then displaces TRIF to turn off the signal (‘OFF’), with TLR4 ultimately being degraded in the late endosome. TBK1
also undergoes K63-linked ubiquitination, mediated by Nrdp1. (B) At the endosome, TLR3, which is involved in the sensing of West Nile virus,
influenza virus, HCV and Epstein-Barr virus (EBV; via the sensing of EBER), engages with TRIF and TRAF3 (which is modified by K63-linked ubiq-
uitination) to activate TBK1. TLR2 has also been shown to engage at the endosome with TBK1 via the MAL–MyD88 complex, in response to
vaccinia and murine cytomegalovirus (MCMV). Recent findings on endosomal TLR7 indicate an important role in leukocyte trafficking in response
to West Nile virus, reactivation of HSV in response to vesicular stomatitis virus and finally in the pathogenesis of AIDS by HIV.
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R329type I IFN induction. Barbalat et al. [10] showed that vaccinia
and murine cytomegalovirus can induce type I IFNs via TLR2.
A particular cell type in the bone marrow and spleen —
Ly6Chi inflammatory monocytes — was shown to be the
key cell type involved in this response, which may explain
why this phenomenon was missed in previous studies.
Known bacterial ligands for TLR2 were unable to drive this
IFN response, which was shown to require TLR2 internalisa-
tion. TLR2 can therefore recognize a viral-associated molec-
ular pattern and drive type I IFN production.
A further insight into the role of TLRs in viral diseases
came from Town et al. [11], who showed that deficiency
in either TLR7 or MyD88 dramatically impaired leukocyte
homing during infection with West Nile virus, resulting in
increased mortality and higher viral burdens. Interestingly,
IL-23, which is required for acquired immunity and leukocyte
trafficking, was shown to be a particularly important effector
cytokine in this model of infection. TLR7 activation by
West Nile virus has also been shown to promote migration
of Langerhans cells from the skin to lymph nodes, which
could be an important mechanism for triggering adaptive
immunity to the virus [12]. The current treatment for West
Nile viral infection is very limited, so TLR7 agonists might
be of use here.A different study, however, showed that ligation of TLR7
might actually affect viral latency [13]. Agonists specific
for TLR7/8 have been shown to reactivate latent Kaposi’s
sarcoma-associated herpesvirus, inducing viral lytic gene
transcription and replication. Vesicular stomatitis virus,
which is sensed by TLR7/8, also reactivated this herpes virus
from latency, suggesting that infections sensed by TLR7
might be important triggers for episodic reactivation of latent
herpes viruses.
TLR7 has also proved to be relevant to HIV pathogenesis
as it may be important for explaining why HIV-1-infected
women tend to have lower viral loads early in HIV-1 infection
but progress more quickly to AIDS for a given viral load
compared with men [14]. Meier et al. [14] demonstrated
significant sex differences in the response of plasmacytoid
dendritic cells to HIV. Plasmacytoid dendritic cells from
women produced markedly more IFNa in response to HIV-
1-encoded TLR7 ligands when compared with those from
men. Considerably higher levels of CD8+ T-cell activation
were also found in treatment-naı¨ve women chronically
infected with HIV-1. It is likely that there is higher immune
activation in women in response to HIV, which might lead
to faster HIV disease progression. The mechanism here is
not clear but could involve the presence of increased cell
Current Biology Vol 20 No 7
R330numbers (both dendritic cells and CD4+ T cells) for infection
by the virus and possibly enhanced infection due to induc-
tion of receptors such as the C-type lectin DC-SIGN on
dendritic cells. The data suggest that inhibition of the TLR7
pathway in plasmacytoid dendritic cells might represent
a new approach for treating HIV-1 infection.
Apart from TLR7, another TLR recently implicated in
the pathogenesis of human viral disease is TLR3. Most
Epstein-Barr virus (EBV) infections are asymptomatic, but
in certain cases the virus can trigger infectious mononucle-
osis and EBV-associated hemophagocytic lymphohistiocy-
tosis, thought to be a result of sudden release of inflamma-
tory cytokines. Iwakiri et al. [15] showed that this cytokine
production is probably induced by the release of small viral
RNAs called EBERs from infected cells, which activate
immune cells (probably human blood dendritic cells) via
TLR3 signalling to produce IFNg and TNF. EBERs are non-
coding RNAs that form stem-loop structures by intermolec-
ular base-pairing, giving rise to double-stranded RNA
(dsRNA)-like molecules. Thus, TLR3 significantly contributes
to the pathogenesis of EBV infection.
Cytosolic Detection of Viruses by NLRs and RLRs
Viral infection is known to promote IL-1b production, which
is important for the inflammatory response to viruses and
also for the induction of fever, an important clinical feature
of viral diseases. IL-1b is produced in a pro-IL-1b form
that must be cleaved by caspase-1 to become active.
Caspase-1 is found within multiprotein complexes termed
inflammasomes, the best-characterized of which contains
the NLR NALP3, which has been shown to be required for
IL-1b processing in response to both adenovirus [16] and
RNA derived from influenza (Figure 2) [17]. NALP3 is unlikely
to bind directly to viral nucleic acids, however, and is more
likely to sense an as yet ill-defined event, possibly membrane
perturbation. In addition to NALP3, an IFN-inducible HIN-200
family protein termed AIM2 has been shown to activate cas-
pase-1 in response to cytosolic DNA [5,18–20] and vaccinia
[5] (Figure 2). Apart from its DNA-binding HIN domain,
AIM2 (like NALP3) has a pyrin domain, the domain required
for recruitment of caspase-1 via the inflammasome compo-
nent ASC. Both NALP3 and AIM2 are likely to be important
for the induction of fever during viral infections and also for
the production of IL-18, which is an important cytokine for
promoting responses from type 1 T helper cells during viral
infections.
Similar to NALP3 and AIM2, the RLR RIG-I has also now
been shown to mediate IL-1b production in response to
certain viruses. Poeck et al. [21] showed that RIG-I-depen-
dent viruses and a synthetic RIG-I ligand were capable
of activating the caspase-1-dependent inflammasome in a
NALP3-independent manner by a novel pathway involving
a complex containing RIG-I and ASC, and not requiring the
adapter protein MAVS [21] (Figure 2) — the first example of
MAVS-independent RIG-I signaling. In contrast, viruses
sensed by the RLR MDA5 did require NALP3 for inflamma-
some activation [21].
NOD2 is another NLR that has recently been implicated in
the anti-viral response. NOD2 was previously thought only to
sense the bacterial peptidoglycan breakdown product mur-
amyl dipeptide, but it has now been shown to bind viral
single-stranded RNA (ssRNA) and activate IRF3, leading to
IFNb production [22]. NOD2 was also shown to sense Rous
sarcoma virus and mediate viral killing in 293 cells and wasrequired in vivo for host defense against this virus. NOD2
signaled via MAVS, which again is something of a surprise,
as MAVS was thought to be involved only in RLR signaling
(Figure 2).
Although RLRs now have an established role in the cyto-
solic detection of multiple RNA viruses [23], it is only very
recently that the exact viral RNA moiety they recognize has
become apparent. For RIG-I, previous reports had shown
that a 50 triphosphate group in the RNA ligand was required
for stimulating this RLR, which had superseded the idea
that RIG-I recognizes dsRNA, since some ssRNAs with 50
triphosphate groups are also recognized [24,25]. However,
two groups recently showed that pure ssRNA with a 50
triphosphate group is unable to activate RIG-I [26,27].
Rather, when using chemically synthesized oligoribonucleo-
tides, the optimal RIG-I agonist was shown to be blunt-
ended 50 triphosphate dsRNA at least 20 base pairs in length
[27]. The reason for the previous confusion is that in vitro
transcribed ssRNA often contains base-paired structures
as a result of ‘copy back’ from the 30 end. These studies
explain how RIG-I detects negative-stranded RNA viruses,
such as rabies, which lack stretches of dsRNA but contain
blunt, short 50 triphosphate dsRNA in the panhandle region
of their single-stranded genome [26,27]. For MDA5, it had
been assumed that the ligand for this RLR was long dsRNA,
and indeed Pichlmair et al. [28] showed that RNA extracted
from cells infected with encephalomyocarditis virus or
vaccinia could induce MDA5-dependent type I IFN produc-
tion. However, the stimulatory activity of the RNA resided
in higher-order structures containing both ssRNA and
dsRNA, leading the authors to conclude that MDA5 recog-
nises branched RNA in web-like structures rather than long
linear molecules of dsRNA.
As is the case for TLRs, new roles for ubiquitin and E3
ligases have recently been revealed in the RLR signaling
pathways. It was already known that the E3 ligase TRIM25
can positively regulate RIG-I, while, similar to TLR3/4-medi-
ated IRF3 activation, TRAF3 also has a role in RLR signaling
and IRF3 activation downstream of MAVS [29]. The impor-
tance of ubiquitination in the RLR pathway was further un-
derscored by Zeng et al. [30], who showed that the ubiqui-
tin-conjugating enzyme (E2) Ubc5 has an essential role in
IRF3 activation downstream of MAVS, probably by cata-
lyzing the addition of K63-linked chains to components of
the MAVS signaling complex, to recruit TBK1 via the ubiqui-
tin-binding domains of NEMO.
In another study, a novel pathway that downregulates
RLR signaling via degradation of MAVS was uncovered
[31]. This pathway involves the protein PCBP2, which was
previously shown to have a role in regulating mRNA stability
and translation, but was shown here to be upregulated
in response to viral infection and to interact with MAVS.
PCBP2 mediated MAVS degradation by recruiting the E3
ligase AIP4 to polyubiquitinate MAVS. In cells lacking AIP4,
the RLR-mediated antiviral response was exaggerated and
prolonged [31]. Thus, although PCBP2 has a defined role in
regulation of RNA stability and translation, it can also ‘moon-
light’ as a more direct regulator of innate immune signaling.
This is reminiscent of another recently identified component
of RLR signaling, DEAD-box protein 3 (DDX3), which has
a well-defined role in multiple aspects of RNA metabolism
but has now also been shown to directly regulate the TBK1–
IKK3 complex required for IRF3 activation downstream of
RIG-I [32,33].
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Figure 2. Recent developments in viral nucleic acid cytosolic detection pathways.
A number of novel receptors for viral nucleic acid have recently been identified, mediating both IL-1b and IFNb production. Production of IL-1b in
response to viruses requires activation of the inflammasome, which involves ASC and caspase-1. For vaccinia, inflammasome activation requires
the upstream DNA sensor AIM2, for vesicular stomatitis virus (VSV), RIG-I is required, while for influenza, adenovirus, modified vaccinia Ankara
virus (MVA) and encephalomyocarditis virus (EMCV), NALP3 is essential. MAVS is a central player in the activation of the TBK1 complex via
a process requiring TRAF3-dependent formation of K63-linked ubiquitin chains, and involving the signaling components DDX3 and STING.
The TBK1 complex phosphorylates IRF3 and IRF7, leading to induction of IFNa and IFNb. Multiple upstream nucleic-acid-sensing receptors
detect viruses and access this MAVS pathway: RIG-I for many RNA viruses, including rabies and VSV; MDA5 for vaccinia, EMCV and MVA;
and NOD2 for RSV. Further, RNA polymerase III transcribes DNA from EBV, HSV and adenovirus into RNA ligands for RIG-I that also stimulate
the MAVS pathway. CMV has been shown to activate the TBK1 complex in a DAI- and DDX3-dependent manner, via a poorly characterized
signaling pathway, while HSV and other viruses also act through STING to activate TBK1, which may involve as yet undiscovered DNA sensors.
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One area of recent intense research has been the search for
cytosolic DNA-sensing pathways that would account for the
ability of exogenously added DNA (such as that introduced
by invading DNA viruses) to induce IFNb, and also for the
adjuvant effect of non-TLR9-activating DNA in vaccines.
DAI/ZBP1, a Z-DNA binding protein, was the first such
receptor identified in recent years, and it was initially shown
that DAI expression in murine L929 fibroblasts led to
enhanced IFNb induction by multiple types of exogenously
added DNA, including viral DNA [34]. However, the role of
DAI is cell-type specific, and it may not be relevant to the
majority of viruses, since knocking down DAI expression in
other cell types by siRNA had very little effect on cellular
responses to exogenous DNA [35,36]. One virus that hasbeen recently linked to DAI is human cytomegalovirus; in
transformed human fibroblasts DAI had a role in stimulation
of innate immune signaling in response to the virus, and was
also required to restrict viral replication [37]. Interestingly,
DDX3 was also implicated in sensing cytomegalovirus, while
MAVS was dispensable, demonstrating a role for DDX3 not
only in RLR signaling but also in DNA-sensing pathways
[37] (Figure 2). Importantly, though, in cells from DAI-defi-
cient mice responses to poly(dA-dT), a synthetic dsDNA
that seems to induce IFNb in all cell types, were normal
[38], and DAI, but not TBK1, was also dispensable for DNA-
vaccine-induced immunogenicity [38]. Clearly other DNA
sensor pathways must exist that initiate signaling leading
to TBK1 activation and subsequent systemic responses
to DNA.
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implicated in DNA-mediated innate immune and vaccine
adjuvant responses is the membrane protein STING (also
known as MITA). Previously, siRNA-mediated knockdown
of STING/MITA revealed that it is a novel downstream
component of both RLR-mediated and DNA-sensing path-
ways that induce IFN production [39,40]. Recent studies in
STING-deficient mice confirmed that STING has an essential
role in mediating IFN induction in response to exogenous
DNA, and vesicular stomatitis virus and herpes simplex virus,
and also in promoting cytotoxic T-cell responses to plasmid
DNA vaccination [41].
A novel DNA sensor pathway that accounts for the
response of many cells to poly(dA-dT) was unexpectedly
found to involve RIG-I and MAVS [42–44]. In HEK293 cells,
poly(dA-dT)-induced IFNb was impaired by siRNA-mediated
knockdown of RIG-I and MAVS, but not MDA5 [42,44]. Inter-
estingly, HEK293 cells only seem to induce IFNb in response
to poly(dA-dT) and not other types of DNA (which probably
explains their usefulness in DNA plasmid transfection
studies). Surprisingly, the poly(dA-dT)–RIG-I–MAVS–IFNb
response was shown to require the transcription of pol-
y(dA-dT) into a RIG-I RNA agonist by RNA polymerase III
(Pol III), thus implicating yet another protein with a classical
role in RNA biology in innate immune sensing. The role of
Pol III–RIG-I in sensing DNA seems less restricted than that
of DAI in terms of cell type, since it can at least partly account
for poly(dA-dT) responses in human cell lines [42], and in
primary human and murine dendritic cells [44]. DNA sensing
via RIG-I–Pol III has also been linked to DNA viruses, since
inhibition of Pol III blocked the ability of EBV EBERs to
induce IFN [44], and prevented the induction of IFN by
adenovirus [42,43] and herpes simplex virus [42] in cell lines.
The role of Pol III–RIG-I in responding to DNA viruses in
primary cells and the particular viruses to which this pathway
responds in vivo remain to be clarified. Further, we can
assume that other DNA sensors that account for the innate
immune response to DNA viruses are yet to be discovered
(Figure 2).
Conclusions
How innate immune receptors sense viruses has been an
area of immunological research that has seen remarkable
progress in the past five years. TLRs, RLRs, NLRs and the
HIN200 family of proteins have all been implicated, and the
complexities of the signaling pathways that are activated
by these receptors continue to be revealed. However, there
is still a need to prove decisively which receptors or, more
likely, which combination of receptors are detecting live
viruses in primary cells, and there remain a number of
important questions. Firstly, how are the various receptor
systems integrated and what precise effector mechanisms
are engaged? This is an important challenge for the develop-
ment of new vaccines since an optimal adjuvant will likely
engage with multiple receptor systems. Secondly, what
receptors remain to be discovered, given that, for example
in the case of DNA sensing, our understanding remains
incomplete? Thirdly, and perhaps most challengingly, how
do these systems relate to human viral disease pathogen-
esis? Ongoing studies are focusing on these questions,
and the answers will provide important information that will
hopefully lead to new treatments, both preventive and ther-
apeutic, for the many viral diseases that remain a burden
on humanity.Acknowledgements
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